ArticleTranslational cancer research2026
SERPINH1, a regulatory factor of oligodendroglioma cell invasion and extracellular matrix secretion, as a novel prognostic biomarker and therapeutic target.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oligodendroglioma is a specific type of brain glioma, and relatively little research has been conducted on it. The expression and prognosis of serine protease peptidase inhibitor, branch H, member 1 (SERPINH1) in some malignant tumors have been studied, but the prognosis value and potential mechanism of this gene in oligodendroglioma have not been reported yet, and further research is needed. This study aims to reveal the expression characteristics and biological functions of SERPINH1 in oligodendroglioma cells, laying the foundation for targeted drug development. Methods: Retrospective RNA sequencing (RNA-seq) data analysis was conducted in a cohort of 171 patients with oligodendroglioma in the Chinese Glioma Genome Atlas (CGGA) database and 149 patients in The Cancer Genome Atlas (TCGA) database. In addition, we used Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Kaplan-Meier analyses, univariate and multivariate Cox regression analyses, correlation analysis, as well as Kolmogorov-Smirnov test and Unpaired Results: SERPINH1 is highly enriched in short-lived patients compared to long-lived oligodendroglioma patients. SERPINH1 is relatively highly expressed in more malignant oligodendrogliomas. Functional enrichment shows that SERPINH1 is closely related to the tumor invasion function of oligodendroglioma. Further research has confirmed that SERPINH1 promotes the invasive function of tumor cells by regulating the secretion of extracellular matrix. Prognostic analysis shows that SERPINH1 is an independent poor prognostic factor for oligodendroglioma. Conclusions: We found that SERPINH1 can serve as an independent prognostic biomarker for oligodendroglioma. It may be a potential new target for the treatment of oligodendroglioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.